Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa ...

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development.

Sanofi (NASDAQ:SNY) said on Thursday its multiple myeloma drug Sarclisa (isatuximab) met the primary endpoints of a late-stage trial. The drug is currently indicated for use in a combination ...

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.

The artwork of Mister Cartoon can be seen pretty much everywhere — tattooed on celebrities, exhibited in art galleries, airbrushed on cars, painted on public walls and printed on team jerseys.

After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood disorder.

Sanofi’s market cap boost coincided with an FDA approval for first-line multiple myeloma drug Sarclisa and nods in Europe and the U.S. for anti-inflammatory juggernaut Dupixent to treat chronic ...